Volume 66, 2022-12-1, Pages i-226
Articles in this issue:
1. Editorial Board
2. Mammographic breast density and the risk of breast cancer: A systematic review and meta-analysis
- Pages 62-68. Bodewes, F.T.H., van Asselt, A.A., Dorrius, M.D., Greuter, M.J.W., and de Bock, G.H..
- PDF
3. Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis
- Pages 126-135. Lin, Ying-Yi, Gao, Hong-Fei, Yang, Xin, Zhu, Teng, Zheng, Xing-xing, Ji, Fei, Zhang, Liu-Lu, Yang, Ci-Qiu, Yang, Mei, Li, Jie-Qing, Cheng, Min-Yi, and Wang, Kun.
- PDF
4. Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
- Pages 145-156. Aapro, Matti, Cardoso, Fatima, Curigliano, Giuseppe, Eniu, Alexandru, Gligorov, Joseph, Harbeck, Nadia, Mueller, Andreas, Pagani, Olivia, Paluch-Shimon, Shani, Senkus, Elzbieta, Thürlimann, Beat, and Zaman, Khalil.
- PDF
5. Acinic cell carcinoma of the breast: A comprehensive review
- Pages 208-216. Ajkunic, Azra, Skenderi, Faruk, Shaker, Nada, Akhtar, Saghir, Lamovec, Janez, Gatalica, Zoran, and Vranic, Semir.
- PDF
6. PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology
- Pages 293-304. Miglietta, Federica, Cinquini, Michela, Dieci, Maria Vittoria, Cortesi, Laura, Criscitiello, Carmen, Montemurro, Filippo, Del Mastro, Lucia, Zambelli, Alberto, Biganzoli, Laura, Levaggi, Alessia, Delle Piane, Chiara, Marchiò, Caterina, Calabrese, Massimo, Fortunato, Lucio, Franco, Pierfrancesco, Meduri, Bruno, Fittipaldo, Veronica Andrea, and Gori, Stefania.
- PDF
7. Does neoadjuvant chemotherapy regimen affect sarcopenia status in patients with breast cancer?
- Pages 1-7. Jang, Min Kyeong, Park, Seho, Park, Chang, Doorenbos, Ardith Z., Go, Jieon, and Kim, Sue.
- PDF
8. Nomogram for predicting overall survival in patients with triple-negative apocrine breast cancer: Surveillance, epidemiology, and end results-based analysis
- Pages 8-14. Xu, Yinggang, Zhang, Weiwei, He, Jinzhi, Wang, Ye, Chen, Rui, Shi, Wenjie, Wan, Xinyu, Shi, Xiaoqing, Huang, Xiaofeng, Wang, Jue, and Zha, Xiaoming.
- PDF
9. Current and future burden of breast cancer: Global statistics for 2020 and 2040
- Pages 15-23. Arnold, Melina, Morgan, Eileen, Rumgay, Harriet, Mafra, Allini, Singh, Deependra, Laversanne, Mathieu, Vignat, Jerome, Gralow, Julie R., Cardoso, Fatima, Siesling, Sabine, and Soerjomataram, Isabelle.
- PDF
10. Treatment and survival outcomes in older women with primary breast cancer: A retrospective propensity score-matched analysis
- Pages 24-30. Sang, Yuting, Yang, Benlong, Mo, Miao, Liu, Shiyang, Zhou, Xujie, Chen, Jiajian, Hao, Shuang, Huang, Xiaoyan, Liu, Guangyu, Shao, Zhimin, and Wu, Jiong.
- PDF
11. A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer
- Pages 31-39. Jia, Xiaomeng, Wang, Kainan, Xu, Lingzhi, Li, Ning, Zhao, Zuowei, and Li, Man.
- PDF
12. Prognosis stratification and postoperative radiation therapy utilization in adenoid cystic carcinoma of the breast
- Pages 40-48. Zhang, Di, Li, Lixi, and Ma, Fei.
- PDF
13. Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?
- Pages 49-53. Bilani, Nadeem, Crowley, Fionnuala, Mohanna, Mohamed, Itani, Mira, Yaghi, Marita, Saravia, Diana, Jabbal, Iktej, Dominguez, Barbara, Liang, Hong, and Nahleh, Zeina.
- PDF
14. Suggestion for the omission of post-mastectomy chest wall radiation therapy in patients who underwent skin-sparing/nipple-sparing mastectomy
- Pages 54-61. Kim, Nalee, Park, Won, Cho, Won Kyung, Kim, Hae Young, Choi, Doo Ho, Nam, Seok Jin, Kim, Seok Won, Lee, Jeong Eon, Yu, Jonghan, Chae, Byung Joo, Lee, Se Kyung, Ryu, Jai Min, Mun, Goo-Hyun, Pyon, Jai-Kyong, and Jeon, Byung-Joon.
- PDF
15. Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer
- Pages 69-76. Bahl, Amit, Wilson, William, Ball, Jessica, Renninson, Emily, Dubey, Sidharth, Bravo, Alicia, Foulstone, Emily, Spensley, Saiqa, Bowen, Rebecca, Mansi, Janine, Waters, Simon, Riddle, Pippa, Wheatley, Duncan, Stephens, Peter, Bezecny, Pavel, Madhusudan, Srinivasan, Verrill, Mark, Braybrooke, Jeremy, Comins, Charles, Mohan, Vivek, Gee, Abigail, Kirk, Hannah, Markham, Alison, Evans, Heidi, Watson, Eve, Callaway, Mark, Pearson, Sylvia, Hackshaw, Allan, and Churn, Mark.
- PDF
16. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
- Pages 77-84. Salvador Bofill, Javier, Moreno Anton, Fernando, Rodriguez Sanchez, Cesar Augusto, Galve Calvo, Elena, Hernando Melia, Cristina, Ciruelos Gil, Eva Maria, Vidal, Maria, Jiménez-Rodriguez, Begoña, De la Cruz Merino, Luis, Martínez Jañez, Noelia, Villanueva Vazquez, Rafael, de Toro Salas, Ruben, Anton Torres, Antonio, Alvarez Lopez, Isabel Manuela, Gavila Gregori, Joaquin, Quiroga Garcia, Vanesa, Vicente Rubio, Elena, De la Haba-Rodriguez, Juan, Gonzalez-Santiago, Santiago, Diaz Fernandez, Nieves, Barnadas Molins, Agusti, Cantos Sanchez de Ibargüen, Blanca, Delgado Mingorance, Juan Ignacio, Bellet Ezquerra, Meritxell, de Casa, Sonia, Gimeno, Asuncion, and Martin, Miguel.
- PDF
17. Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
- Pages 85-88. Yıldırım, Hasan Çağrı, Mutlu, Emel, Chalabiyev, Elvin, Özen, Miraç, Keskinkılıç, Merve, Ön, Sercan, Çelebi, Abdussamet, Dursun, Bengü, Acar, Ömer, Kahraman, Seda, Aykan, Musa Barış, Kaman, Ömür, Doğan, Akif, Erdoğan, Atike Pınar, Melisa Celayir, Özde, Günenç, Damla, Güven, Deniz Can, Vedat Bayoğlu, İbrahim, Yavuzşen, Tuğba, Hacıbekiroğlu, İlhan, İnanç, Mevlüde, Kılıçkap, Saadettin, Yalçın, Şuayib, and Aksoy, Sercan.
- PDF
18. Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study
- Pages 89-96. Xie, Yuxin, Yang, Libo, Wu, Yanqi, Zheng, Hong, and Gou, Qiheng.
- PDF
19. Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis
- Pages 97-109. Li, Shiqi, Zhang, Ying, Zhang, Peigen, Xue, Shuijing, Chen, Yu, Sun, Lihua, and Yang, Rui.
- PDF
20. Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study
- Pages 110-117. Reinisch, Mattea, Untch, Michael, Mahlberg, Rolf, Reimer, Toralf, Hitschold, Thomas, Marmé, Frederik, Aydogdu, Mustafa, Schmatloch, Sabine, Lück, Hans-Joachim, Schmidt, Marcus, Ladda, Ekkehart, Sinn, Bruno Valentin, Klare, Peter, Janni, Wolfgang, Jackisch, Christian, Denkert, Carsten, Seiler, Sabine, Göhler, Thomas, Michel, Laura, Burchardi, Nicole, Stickeler, Elmar, Rey, Julia, Klutinus, Nicole, Möbus, Volker, and Loibl, Sibylle.
- PDF
21. Imaging of lumpectomy surface with large field-of-view confocal laser scanning microscope for intraoperative margin assessment - POLARHIS study
- Pages 118-125. Sandor, Mariana-Felicia, Schwalbach, Beatrice, Hofmann, Viktoria, Istrate, Simona-Elena, Schuller, Zlatna, Ionescu, Elena, Heimann, Sara, Ragazzi, Moira, and Lux, Michael P..
- PDF
22. Influence of age as a continuous variable on the prognosis of patients with pT1-2N1 breast cancer
- Pages 136-144. Zhao, Xu-Ran, Tang, Yu, Wu, Hong-Fen, Guo, Qi-Shuai, Zhang, Yu-Jing, Shi, Mei, Cheng, Jing, Wang, Hong-Mei, Liu, Min, Ma, Chang-Ying, Wen, Ge, Wang, Xiao-hu, Fang, Hui, Jing, Hao, Song, Yong-Wen, Jin, Jing, Liu, Yue-Ping, Chen, Bo, Qi, Shu-Nan, Li, Ning, Tang, Yuan, Lu, Ning-Ning, Zhang, Na, Li, Ye-Xiong, and Wang, Shu-Lian.
- PDF
23. Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
- Pages 157-161. Del Re, Marzia, Crucitta, Stefania, Omarini, Claudia, Bargagna, Irene, Mongillo, Marta, Palleschi, Michela, Stucci, Stefania, Meattini, Icro, D'Onofrio, Raffaella, Lorenzini, Giulia, Biondani, Pamela, De Giorgi, Ugo, Porta, Camillo, Livi, Lorenzo, Natalizio, Salvatore, Fontana, Andrea, Giontella, Elena, Angelini, Lucia, Fogli, Stefano, and Danesi, Romano.
- PDF
24. Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy
- Pages 162-168. Pedersini, Rebecca, di Mauro, Pierluigi, Amoroso, Vito, Castronovo, Vincenza, Zamparini, Manuel, Monteverdi, Sara, Laini, Lara, Schivardi, Greta, Cosentini, Deborah, Grisanti, Salvatore, Marelli, Sara, Ferini Strambi, Luigi, and Berruti, Alfredo.
- PDF
25. The impact of standardized structured reporting of pathology reports for breast cancer care
- Pages 178-182. Snoek, J.A.A., Nagtegaal, I.D., Siesling, S., van den Broek, E., van Slooten, H.J., and Hugen, N..
- PDF
26. Deep learning with biopsy whole slide images for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer：A multicenter study
- Pages 183-190. Li, Bao, Li, Fengling, Liu, Zhenyu, Xu, FangPing, Ye, Guolin, Li, Wei, Zhang, Yimin, Zhu, Teng, Shao, Lizhi, Chen, Chi, Sun, Caixia, Qiu, Bensheng, Bu, Hong, Wang, Kun, and Tian, Jie.
- PDF
27. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis
- Pages 191-198. Zhu, Youwen, Liu, Kun, Wang, Min, Wang, Kailing, and Zhu, Hong.
- PDF
28. Inclusion of premenopausal women in breast cancer clinical trials
- Pages 204-207. Corrigan, Kelsey L., Kouzy, Ramez, Jaoude, Joseph Abi, Patel, Roshal R., Layman, Rachel M., Giordano, Sharon H., Woodward, Wendy A., Smith, Benjamin D., Shaitelman, Simona F., and Ludmir, Ethan B..
- PDF
29. Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancer
- Pages 227-235. Kerin, Eoin P., Davey, Matthew G., McLaughlin, Ray P., Sweeney, Karl J., Barry, Michael K., Malone, Carmel M., Elwahab, Sami Abd, Lowery, Aoife J., and Kerin, Michael J..
- PDF
30. Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel
- Pages 236-244. Mahtani, Reshma, Niyazov, Alexander, Arondekar, Bhakti, Lewis, Katie, Rider, Alex, Massey, Lucy, and Lux, Michael Patrick.
- PDF
31. Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study
- Pages 245-254. Sawaki, Masataka, Taira, Naruto, Uemura, Yukari, Saito, Tsuyoshi, Baba, Shinichi, Kobayashi, Kokoro, Kawashima, Hiroaki, Tsuneizumi, Michiko, Sagawa, Noriko, Bando, Hiroko, Takahashi, Masato, Yamaguchi, Miki, Takashima, Tsutomu, Nakayama, Takahiro, Kashiwaba, Masahiro, Mizuno, Toshiro, Yamamoto, Yutaka, Iwata, Hiroji, Toyama, Tatsuya, Tsugawa, Koichiro, Kawahara, Takuya, and Mukai, Hirofumi.
- PDF
32. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer
- Pages 255-261. Zhou, Jinmei, Wu, Xuexue, Zhang, Huiqiang, Wang, Xiaobo, Yuan, Yang, Zhang, Shaohua, Jiang, Zefei, and Wang, Tao.
- PDF
33. Trastuzumab-based regimens beyond progression: A crucial treatment option for HER2+ advanced/metastatic breast cancer
- Pages 262-271. Sanglier, Thibaut, Ross, Ryan, Shi, Tianlai, Mouta, João, Swain, Sandra, and Cardoso, Fatima.
- PDF
34. Reproductive risk factors associated with breast cancer in young women by molecular subtype
- Pages 272-277. Ruddy, Kathryn J., Vierkant, Robert A., Jahan, Nusrat, Higgins, Alexandra, Partridge, Ann, Larson, Nicole, Radisky, Derek C., Couch, Fergus, Olson, Janet, and Sherman, Mark E..
- PDF
35. Real-world data of HER2-low metastatic breast cancer: A population based cohort study
- Pages 278-284. Holthuis, Emily I., Vondeling, Gerard T., Kuiper, Josephina G., Dezentjé, Vincent, Rosenlund, Mats, Overbeek, Jetty A., and van Deurzen, Carolien H.M..
- PDF
36. Patterns of care over 10 years in young breast cancer patients in the Netherlands, a nationwide population-based study
- Pages 285-292. Maliko, Nansi, Bijker, Nina, Bos, Monique EMM., Wouters, Michel WJM., and Vrancken Peeters, Marie-Jeanne TFD..
- PDF
37. Mondor's disease of the breast: A cutaneous thromboembolic manifestation of Covid-19?
- Pages 305-309. Renshaw, Lorna, Dixon, J Michael, Anderson, Julia, and Turnbull, Arran K..
- PDF
38. Adjuvant aromatase inhibitor treatment worsens depressive symptoms and sleep quality in postmenopausal women with localized breast cancer: A one-year follow-up study
- Pages 310-316. García-Sánchez, Javier, Mafla-España, Mayra Alejandra, Torregrosa, María Dolores, and Cauli, Omar.
- PDF
39. Application of thermoplastic elastomer (TPE) bolus in postmastectomy radiotherapy
- Pages 317-323. Gong, Pan, Dai, Guyu, Wu, Xiaoyu, Wang, Xuetao, Xie, Li, Xu, Shuni, and Zhong, Renming.
- PDF
40. Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3
- Pages 324-331. Rugo, Hope S., Im, Seock-Ah, Joy, Anil A., Shparyk, Yaroslav, Walshe, Janice M., Sleckman, Bethany, Loi, Sherene, Theall, Kathy Puyana, Kim, Sindy, Huang, Xin, Bananis, Eustratios, Mahtani, Reshma, Finn, Richard S., and Diéras, Véronique.
- PDF
41. Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL
- Pages 332-341. Longo, Benedetto, Di Napoli, Arianna, Curigliano, Giuseppe, Veronesi, Paolo, Pileri, Stefano, Martelli, Maurizio, De Vita, Roy, Felici, Nicola, Cirillo, Pierfrancesco, Bernardi, Claudio, D'orsi, Gennaro, Giacalone, Martina, Storti, Gabriele, and Cervelli, Valerio.
- PDF
42. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
- Pages 169-177. Shastry, Mythili, Jacob, Saya, Rugo, Hope S., and Hamilton, Erika.
- PDF
43. Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy
- Pages 199-203. Jeong, Jae Ho, and Kim, Sung-Bae.
- PDF
44. Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
- Pages 217-226. Rassy, Elie, Rached, Layal, and Pistilli, Barbara.
- PDF